

CITATION REPORT

List of articles citing

Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis

DOI: 10.1111/apt.12758

Alimentary Pharmacology and Therapeutics, 2014, 39, 1276-8

Source: <https://exaly.com/paper-pdf/58315579/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
315	Non-alcoholic fatty liver disease in children: focus on nutritional interventions. 2014 , 6, 4691-705		24
314	Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. 2014 , 20, 15518-31		111
313	Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. 2014 , 15, 2501-11		6
312	Editorial: probiotics in NASH - more studies are needed; authorsPreply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 212	6.1	
311	Editorial: probiotics in NASH - more studies are needed. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 211-2	6.1	1
310	Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective. 2014 , 20, 17737-45		96
309	NASH and the Cross-Talk Between the Gut and Liver. 2014 , 2, 211-217		1
308	Childhood obesity: a role for gut microbiota?. 2014 , 12, 162-75		41
307	Effects of synbiotic on anthropometry, lipid profile and oxidative stress in obese children. 2015 , 6, 775-82		39
306	Probiotics in Pediatric Liver Disease. 2015 , 49 Suppl 1, S33-6		9
305	Probiotic supplementation and trimethylamine-N-oxide production following a high-fat diet. 2015 , 23, 2357-63		79
304	Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. 2015 , 7, 2597-602		38
303	Gut Microbiota: Association with NAFLD and Metabolic Disturbances. 2015 , 2015, 979515		44
302	Dyslipidemia: Relationship to Insulin Resistance, Fatty Liver, and Sub-Clinical Atherosclerosis. 2015 , 65-79		
301	Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. 2015 , 10, 889-902		79
300	JPEN Journal Club 16. Trial Registries. 2015 , 39, 990-2		3
299	A concise review of non-alcoholic fatty liver disease. 2015 , 239, 192-202		190

298	Mikrobiom zwischen Intestinum und Leber. 2015 , 10, 111-115	
297	Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. 2015 , 48, 923-30	165
296	The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease. 2015 , 6, e91	141
295	Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. 2015 , 39, 1118-25	43
294	The growth potential for dairy probiotics. 2015 , 49, 16-22	48
293	Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. 2015 , 30, 780-6	27
292	Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. 2016 , 22, 8078-93	101
291	Gut Microbiota and Metagenomic Advancement in Digestive Disease. 2016 , 2016, 4703406	2
290	Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. 2016 , 17,	160
289	Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. 2016 , 8,	60
288	Fatty liver disease and obesity in youth. 2016 , 23, 66-71	7
287	Diabetes and Non-Alcoholic Fatty Liver Disease. 2016 , 745-758	
286	Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. 2016 , 311, G1018-G1036	49
285	Lifestyle Interventions Including Nutrition, Exercise, and Supplements for Nonalcoholic Fatty Liver Disease in Children. 2016 , 61, 1375-86	60
284	Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. 2016 , 61, 1365-74	72
283	Pediatric Non-alcoholic Fatty Liver Disease. 2016 , 18, 24	26
282	Fatty liver in adolescents: Mechanisms, clinical features and therapy. 2016 , 65, 1258-1260	1
281	The Gut Microbiota: The Gateway to Improved Metabolism. 2016 , 45, 601-614	24

280	Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn: study protocol for a randomized controlled trial. 2016 , 17, 491	19
279	Clinical advances in pediatric nonalcoholic fatty liver disease. 2016 , 63, 1718-25	35
278	The role of the gut microbiota in NAFLD. 2016 , 13, 412-25	459
277	Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. 2016 , 9, 463-72	28
276	Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. 2016 , 46, 1226-1233	52
275	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. 2016 , 150, 1798-810	84
274	Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice. 2016 , 473, 530-6	69
273	Gut Microbiota of Nonalcoholic Fatty Liver Disease. 2016 , 61, 1268-81	37
272	Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?. 2016 , 150, 1745-1755.e3	86
271	Mechanisms Linking the Gut Microbiome and Glucose Metabolism. 2016 , 101, 1445-54	100
270	Nonalcoholic Fatty Liver Disease and the Gut Microbiome. 2016 , 20, 263-75	58
269	Patient needs and research priorities in probiotics: A quantitative KOL prioritization analysis with emphasis on infants and children. 2016 , 4, 19-28	6
268	Nutritional modulation of gut microbiota - the impact on metabolic disease pathophysiology. 2016 , 28, 191-200	56
267	Microbiota manipulation for weight change. 2017 , 106, 146-161	50
266	Effect of prebiotics of Agave salmiana fed to healthy Wistar rats. 2017 , 97, 556-563	14
265	Western diets, gut dysbiosis, and metabolic diseases: Are they linked?. 2017 , 8, 130-142	103
264	Probiotics for people with hepatic encephalopathy. 2017 , 2, CD008716	48
263	Systematic Review: Nutrition and Physical Activity in the Management of Paediatric Nonalcoholic Fatty Liver Disease. 2017 , 65, 141-149	29

262	Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. 2017 , 42, 948-954	33
261	Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease. 2017 , 46, 217-231	14
260	NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). 2017 , 64, 319-334	382
259	Protective effects of a cocktail of lactic acid bacteria on microcystin-LR-induced hepatotoxicity and oxidative damage in BALB/c mice. 2017 , 7, 20480-20487	4
258	The Use of Probiotics in Pediatric Nonalcoholic Fatty Liver Disease: Teachable Moment or Missed Opportunity?. 2017 , 64, 336-337	1
257	Screening for non-alcoholic fatty liver disease in children: do guidelines provide enough guidance?. 2017 , 18, 1050-1060	14
256	The intestinal microbiome and paediatric liver disease. 2017 , 2, 446-455	15
255	Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. 2017 , 71, 182-197	73
254	Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. 2017 , 64, 413-417	119
253	Microbial metabolites in health and disease: Navigating the unknown in search of function. 2017 , 292, 8553-8559	69
252	NAFLD, Helicobacter species and the intestinal microbiome. 2017 , 31, 657-668	25
251	The Impact of Gut Microbiota on Liver Injury. 2017 , 251-283	
250	Non-alcoholic fatty liver disease. 2017 , 27, 556-560	2
249	The pharmacological management of NAFLD in children and adolescents. 2017 , 10, 1225-1237	9
248	An Overview of Probiotic Research. 2017 , 293-357	1
247	Dysbiosis, Spleen Qi, Phlegm, and Complex Difficulties. 2017 , 29, 128-137	7
246	The gut microbiome and liver cancer: mechanisms and clinical translation. 2017 , 14, 527-539	252
245	Inflammation and Microbiota and Gut Reconditioning. 2017 , 1609-1660	1

244	Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. 2017 , 7, 130-137	33
243	Does Nutrition Matter in Liver Disease?. 2017 , 743-759	2
242	Polyphenols and Intestinal Health. 2017 , 191-210	19
241	Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. 2017 , 9,	100
240	The Relationship Between Probiotics and Dietary Fiber Consumption and Cardiovascular Health. 2017 , 73-90	1
239	Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. 2017 , 9,	793
238	Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. 2017 , 4,	59
237	Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions. 2017 , 9, 102	32
236	The Roles of the Gut Microbiota and Toll-like Receptors in Obesity and Nonalcoholic Fatty Liver Disease. 2017 , 26, 86-96	10
235	Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: a 16-week, randomized, placebo-controlled trial. 2018 , 13, 705-714	35
234	Future of Treatment for Nonalcoholic Steatohepatitis: Can the Use of Safe, Evidence-Based, Clinically Proven Supplements Provide the Answer to the Unmet Need?. 2018 , 63, 1726-1736	5
233	Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders. 2018 , 132, 791-811	23
232	Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. 2018 , 58, 28-36	21
231	Degradation of food-derived opioid peptides by bifidobacteria. 2018 , 9, 675-682	9
230	Fatty Liver Disease. 2018 , 451-462	
229	The role of the gut microbiota in the pathology and prevention of liver disease. 2018 , 60, 1-8	21
228	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. 2018 , 33, 86-98	71
227	Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. 2018 , 22, 175-187	21

226	Characterization of the Stool Microbiome in Hispanic Preschool Children by Weight Status and Time. 2018 , 14, 122-130	14
225	Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial. 2018 , 42, 147-155	40
224	Pediatric Nonalcoholic Fatty Liver Disease: Current Thinking. 2018 , 66, 188-192	19
223	Lipotoxicity and the gut-liver axis in NASH pathogenesis. 2018 , 68, 280-295	324
222	Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. 2018 , 9, 1813	44
221	Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT). 2019 , 1125, 85-100	8
220	An overview on the interplay between nutraceuticals and gut microbiota. 2018 , 6, e4465	17
219	Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease. 2018 , 67, 635-642	6
218	Advances in Pediatric Fatty Liver Disease: Pathogenesis, Diagnosis, and Treatment. 2018 , 47, 949-968	10
217	Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. 2018 , 56, 855-867	21
216	Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. 2018 , 94, 556-565	11
215	Update on Pediatric Fatty Liver Disease. 2018 , 17, 361-366	
214	Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. 2018 , 12, 645-657	18
213	A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease. 2018 , 58, 1-16	21
212	The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. 2018 , 14, 701-706	17
211	The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease. 2018 , 1061, 95-110	10
210	Microbiota, Obesity and NAFLD. 2018 , 1061, 111-125	28
209	Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. 2018 , 76, 822-839	56

208	Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players?. 2018 , 14, 81-87		55
207	The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. 2018 , 6,		10
206	Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. 2018 , 20, 315-329		16
205	Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future?. 2018 , 12, 961-967		8
204	Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. 2018 , 10,		68
203	Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3. 2018 , 13, e0192452		21
202	Food for Liver Health: Probiotics. 2019 , 387-391		
201	Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. 2019 , 17, 1457-1476.e7		23
200	The role of the gut microbiome in chronic liver disease: the clinical evidence revised. 2019 , 1, 214-226		41
199	Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 628-639	6.1	19
198	Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. 2019 , 7, 56-60		28
197	Anti-Obesity Effects of CQPC05 Isolated from Sichuan Pickle in High-Fat Diet-Induced Obese Mice through PPAR- δ Signaling Pathway. 2019 , 7,		24
196	Probiotics for dietary management of non-alcoholic fatty liver disease. 2019 , 17, 1553-1563		8
195	NAFLD in children: new genes, new diagnostic modalities and new drugs. 2019 , 16, 517-530		105
194	Treatment of Metabolic Syndrome in Children. 2019 , 10, 702		16
193	Gut Microbiota and Obesity: A Role for Probiotics. 2019 , 11,		144
192	The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. 2019 , 11,		42
191	A narrative review of factors associated with the development and progression of non-alcoholic fatty liver disease. 2019 , 1, 180		3

190	Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management. 2019 , 10, 89-97		15
189	High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. 2019 , 6, e000315		35
188	Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. 2019 , 12, 1756284819878046		20
187	The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). 2019 , 76, 1541-1558		161
186	Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. 2019 , 110, 139-149		50
185	Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. 2019 , 64, 3402-3412		33
184	Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 144-158	6.1	26
183	Effects of pro-/synbiotic supplementation on anthropometric and metabolic indices in overweight or obese children and adolescents: A systematic review and meta-analysis. 2019 , 44, 269-276		18
182	The role of gut microbiota in liver disease development and treatment. 2019 , 3, 3-18		24
181	Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. 2019 , 13, 447-461		31
180	Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis. 2019 , 78, 319-328		44
179	The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. 2019 , 7,		24
178	Microbial Population Changes and Their Relationship with Human Health and Disease. 2019 , 7,		30
177	Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. 2019 , 5, 11-21		19
176	Intestinal microbiome as a novel therapeutic target for local and systemic inflammation. 2019 , 199, 164-172		28
175	Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?. 2019 , 244, 408-418		9
174	The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity. 2019 , 11,		144
173	Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. 2019 , 9, e017995		97

172	Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. 2019 , 3, 456-470	60
171	The Microbiome and Metabolome in Nonalcoholic Fatty Liver Disease. 2019 , 265-269	
170	Probiotics as a Dietary Intervention for Reducing the Risk of Nonalcoholic Fatty Liver Disease. 2019 , 207-223	3
169	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. 2019 , 209, 22-38	18
168	Effects of probiotic supplementation on the regulation of blood lipid levels in overweight or obese subjects: a meta-analysis. 2019 , 10, 1747-1759	21
167	Obesity and Nonalcoholic Fatty Liver Disease in Children. 2019 , 209-222	0
166	Dietary Interventions in Fatty Liver. 2019 , 245-255	
165	Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?. 2019 , 11,	23
164	NAFLD and Liver Transplantation in Children-Working Group Report From the ILTS Single Topic Conference on NAFLD. 2019 , 103, 68-70	7
163	Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. 2019 , 2019, 1484598	19
162	The good bugs: the use of probiotics in pediatrics. 2019 , 31, 661-669	12
161	Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. 2019 , 1864, 326-334	5
160	Probiotics supplementation for the obesity management; A systematic review of animal studies and clinical trials. 2019 , 52, 228-242	63
159	Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. 2019 , 13, 193-204	39
158	The gut microbiome: Relationships with disease and opportunities for therapy. 2019 , 216, 20-40	272
157	Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease. 2019 , 118 Suppl 1, S55-S61	7
156	Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria. 2019 , 58, 1771-1784	19
155	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. 2019 , 17, 616-629.e26	53

154	Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology?. 2020 , 325, 113160	9
153	Low serum amylase, lipase, and trypsin as biomarkers of metabolic disorders: A systematic review and meta-analysis. 2020 , 159, 107974	17
152	Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. 2020 , 55, 142-158	41
151	Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. 2020 , 39, 613-627	19
150	Treatment of Metabolic Syndrome in Children. 2020 , 93, 215-225	4
149	Pediatric NAFLD: lessons from the gut. 2020 , 9, 534-536	
148	The pharmacological treatment of nonalcoholic fatty liver disease in children. 2020 , 13, 1219-1227	2
147	Nonalcoholic fatty liver disease and colorectal cancer: Correlation and missing links. 2020 , 262, 118507	5
146	Combination of inulin and compound probiotic exert synergism in attenuating HFD-induced obesity but shows gender-difference. 2020 , 34, 319-325	
145	Probiotics for the Treatment of Overweight and Obesity in Humans-A Review of Clinical Trials. 2020 , 8,	21
144	Effects of gut microbiome-targeted therapies on cardiometabolic outcomes in children and adolescents: A protocol for systematic review and meta-analysis. 2020 , 99, e21612	
143	Health Impact and Therapeutic Manipulation of the Gut Microbiome. 2020 , 9,	6
142	Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. 2020 , 7, 361	16
141	Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. 2020 , 21,	39
140	The role of gut microbiota in cancer treatment: friend or foe?. 2020 , 69, 1867-1876	70
139	The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. 2020 , 64, e2000375	17
138	Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial. 2020 , 85, 3611-3617	13
137	Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. 2020 , 9,	40

- 136 Microbial Metabolites: Critical Regulators in NAFLD. **2020**, 11, 567654 12
- 135 An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease. **2020**, 7, 679-679 2
- 134 The Role of Gut Microbiome-Targeted Therapy in Nonalcoholic Fatty Liver Disease. **2020**, 19, 420-428
- 133 Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model. **2020**, 9, 170-182 11
- 132 A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. **2020**, 9, 10
- 131 Multistrain Probiotic Increases the Gut Microbiota Diversity in Obese Pregnant Women: Results from a Randomized, Double-Blind Placebo-Controlled Study. **2020**, 4, nzaa095 7
- 130 Microbiote intestinal et st atopathie m tabolique. **2020**, 34, 130-140
- 129 The food-gut axis: lactic acid bacteria and their link to food, the gut microbiome and human health. **2020**, 44, 454-489 43
- 128 Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. **2020**, 158, 1967-1983.e1 37
- 127 Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. **2020**, 12, 16
- 126 Probiotic Strains and Intervention Total Doses for Modulating Obesity-Related Microbiota Dysbiosis: A Systematic Review and Meta-analysis. **2020**, 12, 21
- 125 Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?. **2020**, 158, 1881-1898 38
- 124 Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. **2020**, 318, G582-G609 15
- 123 Microbial Medicine: Prebiotic and Probiotic Functional Foods to Target Obesity and Metabolic Syndrome. **2020**, 21, 50
- 122 Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease. **2020**, 5, 49 7
- 121 Probiotics as Live Bio-therapeutics: Prospects and Perspectives. **2021**, 83-120 2
- 120 The role of the gut microbiome in graft fibrosis after pediatric liver transplantation. **2021**, 140, 709-724 1
- 119 The Influence of the Microbiome on NAFLD and NASH. **2021**, 17, 15-18 8

118	Gut microbiota and obesity and the body weight regulation. 2021 , 355-373	
117	Effects of therapeutic probiotics on modulation of microRNAs. 2021 , 19, 4	12
116	Nutraceuticals for Non-alcoholic Fatty Liver Disease. 2021 , 141-165	
115	THE THERAPEUTIC IMPACT OF PROBIOTICS ON NONALCOHOLIC FATTY LIVER DISEASE IN PEDIATRICS: A SYSTEMATIC REVIEW. 2021 , 39, e2019226	2
114	Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. 2021 , 18,	3
113	G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment. 2021 , 27, 677-691	7
112	Is Probiotic Supplementation Useful for the Management of Body Weight and Other Anthropometric Measures in Adults Affected by Overweight and Obesity with Metabolic Related Diseases? A Systematic Review and Meta-Analysis. 2021 , 13,	6
111	Health-Promoting Role of Isolated from Fermented Foods. 2021 , 9,	28
110	Gut Microbiota and Obesity in Adults and Children: The State of the Art. 2021 , 9, 657020	10
109	Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. 2021 , 40, 1496-1509	3
108	Microbiota, Inflammation, and Gut Barrier Dysfunction in HCC.	1
107	A randomised placebo controlled trial of VSL#3 probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. 2021 , 21, 144	5
106	Brown Adipose Tissue: New Challenges for Prevention of Childhood Obesity. A Narrative Review. 2021 , 13,	4
105	The Influence of Gut Microbiota on the Cardiovascular System Under Conditions of Obesity and Chronic Stress. 2021 , 23, 31	4
104	Bile Salt Hydrolases: At the Crossroads of Microbiota and Human Health. 2021 , 9,	6
103	Polycystic Ovary Syndrome in Insulin-Resistant Adolescents with Obesity: The Role of Nutrition Therapy and Food Supplements as a Strategy to Protect Fertility. 2021 , 13,	8
102	The Role of the Microbiome in Liver Cancer. 2021 , 13,	4
101	Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. 2021 , 22,	7

100	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. 2021 , 7, CD013157	2
99	Treatment of Nonalcoholic Fatty Liver Disease through Changes in Gut Microbiome and Intestinal Epithelial Barrier.	
98	The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. 2021 , 34, 477-482	2
97	Non-Alcoholic Fatty Liver Disease in Children. 2021 , 57,	1
96	Obesity as the 21st Century's major disease: The role of probiotics and prebiotics in prevention and treatment. 2021 , 42, 101115	7
95	A randomized double-blind placebo controlled pilot study of probiotics in adolescents with severe obesity.. 2021 , 20, 1289-1300	0
94	The promise of the gut microbiome as part of individualized treatment strategies. 2021 ,	12
93	Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. 2021 , 1-18	8
92	Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. 2021 , 35, e21871	5
91	Probiotics in treating with alcoholic liver disease and nonalcoholic fatty liver disease. 1-19	0
90	Probiotic and prebiotic interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. 2021 , 12, 517-529	0
89	Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. 2021 , 123, 154844	4
88	The synergy of dietary supplements LI01 and TC01 in alleviating liver failure in rats treated with D-galactosamine. 2021 , 12, 10239-10252	1
87	The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. 2021 , 27, 22-43	14
86	Nonalcoholic Fatty Liver Disease in Children: Spectrum and Consequences. 2021 , 55, 39-52	
85	Nonalcoholic Fatty Liver Disease in Children. 2016 , 339-362	1
84	Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. 2017 , 2,	30
83	Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. 2020 , 8, 1361-1384	27

82	Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Fatty Liver Disease. 2019 , 20, 222-231	11
81	Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota. 2018 , 28, 84-90	3
80	Bile salt hydrolase-overexpressing strains can improve hepatic lipid accumulation in an NAFLD cell model. 2020 , 64,	6
79	Obese children with fatty liver: Between reality and disease mongering. 2017 , 23, 8277-8282	6
78	Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. 2020 , 26, 1901-1911	11
77	Role of gut microbiota via the gut-liver-brain axis in digestive diseases. 2020 , 26, 6141-6162	17
76	Successful Evolution of a Patient with Obesity, Metabolic Syndrome and Severe Gastro esophageal Reflux after Probiotic Intake. 2015 , 2,	1
75	What is the role of antifibrotic therapies in the current and future management of NAFLD?. 218-225	
74	Pediatric Nonalcoholic Fatty Liver Disease. 2016 , 293-307	
73	The application of probiotics for the treatment of inflammatory bowel diseases, hepatopathy, and infectious diseases. 2017 , 6, 35	
72	Treatment of Nonalcoholic Fatty Liver Disease in Children: A Systematic Review. 2017 , 6,	
71	Possibilities of therapeutic manipulation of the gut microbiota. 2018 , 64, 665-671	1
70	Have Probiotics and Synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review. 2019 , 9, 21-28	0
69	The Influence and Treatment of the Intestinal Microbiome on Child Respiratory Diseases. 2020 , 2, 107-114	
68	NAFLD in Children: Implication for the Future. 2020 , 211-223	
67	Bioprospecting Antimicrobials from : Key Factors Underlying Its Probiotic Action. 2021 , 22,	4
66	Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. 2021 , 12, 761836	5
65	Buffalo Milk as a Source of Probiotic Functional Products. 2021 , 9,	2

64	Metabolic syndrome in children. 2020 , 72, 312-325	1
63	Probiotics and Disease: A Comprehensive Summary-Part 3, Cardiometabolic Disease and Fatigue Syndromes. 2017 , 16, 30-41	1
62	Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease. 2018 , 14, 407-414	8
61	Effects of probiotics combined with dietary and lifestyle modification on clinical, biochemical, and radiological parameters in obese children with NASH/NAFLD: a randomized clinical trial. 2021 ,	1
60	Acute and short-term effects of Lactobacillus paracasei subsp. paracasei 431 and inulin intake on appetite control and dietary intake: A two-phases randomized, double blind, placebo-controlled study.. 2021 , 169, 105855	0
59	Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates.. 2022 , 10,	2
58	Therapeutic applications of probiotics and its regulatory framework. 2022 , 635-665	
57	The Effects of Probiotics and Omega-3 Fatty Acids in Liver Steatosis Induced in Rats by High-Fructose Corn Syrup. 2022 , 2022, 1-14	
56	The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease.. 2021 , 22,	4
55	Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.. 2021 , 12,	9
54	Intestinal Barrier and Permeability in Health, Obesity and NAFLD.. 2021 , 10,	9
53	Probiotic normalization of systemic inflammation in siblings of type 1 diabetes patients: an open-label pilot study.. 2022 , 12, 3306	6
52	NAFLD and the Gut-Liver Axis: Exploring an Undernutrition Perspective.. 2022 ,	3
51	The role of microbiota in nonalcoholic fatty liver disease.. 2022 , e13768	3
50	New progress in research of intestinal microbiota in fatty liver disease. 2021 , 29, 1355-1361	
49	Effects of Probiotics on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. 2021 ,	2
48	Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.. 2021 , 9,	1
47	Bacillus subtilis Supplementation in a High-Fat Diet Modulates the Gut Microbiota and Ameliorates Hepatic Lipid Accumulation in Grass Carp (Ctenopharyngodon idella). 2022 , 7, 94	0

46	Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.. 2022 , 23,	5
45	Periodontal Disease and Nonalcoholic Fatty Liver Disease: New Microbiome-Targeted Therapy Based on the Oral-Gut-Liver Axis Concept. 1	0
44	Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease. 2022 , 2022, 1-15	1
43	Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. 2022 , 9,	0
42	Probiotics for liver disease prevention and treatment. 2022 , 579-588	
41	Gut microbiota in obesity and related comorbidities in children and adolescents: the role of biotics in treatment.	0
40	Research progress of gut microbiota in hepatocellular carcinoma.	0
39	Probiotic Use in Children and Adolescents with Overweight or Obesity: A Scoping Review.	0
38	Novel insights into non-alcoholic fatty liver disease and dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular impairment, and inflammation. 2022 , 12,	2
37	The benefit of probiotics in pediatric non-alcoholic fatty liver disease: a meta-analysis of randomized control trials. Publish Ahead of Print,	1
36	Influences of Oral Administration of Probiotics on Posthepatectomy Recovery in Patients in Child-Pugh Grade. 2022 , 2022, 1-7	
35	The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective. 13,	1
34	Effects of Multispecies Synbiotic Supplementation on Anthropometric Measurements, Glucose and Lipid Parameters in Children With Exogenous Obesity: A Randomized, Double Blind, Placebo-Controlled Clinical Trial (Probesity-2 Trial). 9,	0
33	Adipose tissue, systematic inflammation, and neurodegenerative diseases. 2023 , 18, 38	0
32	Metabolic control by the microbiome. 2022 , 14,	0
31	The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis. 10,	
30	The Biotics Family: Current Knowledge and Future Perspectives in Metabolic Diseases. 2022 , 12, 1263	0
29	The gut microbiota as a vehicle for the prevention and treatment of hepatocellular carcinoma. 2022 , 115225	0

28	Probiotics protect against hepatic steatosis in tris (2-chloroethyl) phosphate-induced metabolic disorder of mice via FXR signaling. 2022 , 169, 113440	0
27	Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) [April 2022] AWMF Registration No.: 021025. 2022 , 60, e733-e801	0
26	Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [April 2022] AWMF-Registernummer: 021025. 2022 , 60, 1346-1421	0
25	Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysis. 2022 , 108294	0
24	Considerations for determining safety of probiotics: A USP perspective. 2022 , 136, 105266	2
23	The Human Gut Microbiome in Health, Disease, and Therapeutics. 2022 , 249-260	0
22	Fecal Microbiota Transplantation in NAFLD Treatment. 2022 , 58, 1559	0
21	Intestinal microbiota in the treatment of metabolically associated fatty liver disease. 10, 11240-11251	1
20	Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. 13,	1
19	Probiotics and non-alcoholic fatty liver disease in children and adolescents: a systematic review. 2022 ,	0
18	Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. 12,	1
17	Effects of probiotic fermented milk on management of obesity studied in high-fat-diet induced obese rat model. 2023 , 5,	0
16	The Role of Microbiome in Nonalcoholic Fatty Liver Disease. 2023 , 107-118	0
15	Lactobacillus plantarum ZJUIDS14 alleviates non-alcoholic fatty liver disease in mice in association with modulation in the gut microbiota. 9,	0
14	Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials. 13,	0
13	Microbiota and Liver Cancer. 2023 , 67-90	0
12	Lactobacillus paracasei AO356 ameliorates obesity by regulating adipogenesis and thermogenesis in C57BL/6J male mice. 2023 , 101, 105404	0
11	Il ruolo del microbiota nell'aumento ponderale associato alla terapia antipsicotica. 2022 , 108-122	0

- 10 Current trends and future perspectives of probiotics on human health: an overview. **2023**, 81-122 ○
- 9 Metabolic-associated fatty liver disease: pharmacological management. **2023**, 319-341 ○
- 8 Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis. **2023**, 102, e32734 ○
- 7 Effect of oral probiotic supplementation in obese children: A systematic review. **2023**, 39, 100489 ○
- 6 The Role of the Stress Response in Metabolic Dysfunction-Associated Fatty Liver Disease: A Psychoneuroendocrineimmunology-Based Perspective. **2023**, 15, 795 ○
- 5 Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP). **2023**, 189, 106679 ○
- 4 Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis. 29, 967-996 ○
- 3 Effects of SCFAs and TMAO on non-alcoholic fatty liver disease indicating the therapeutic benefits of plant-based diet, and supplemental prebiotics, probiotics and synbiotics. **2023**, 66, ○
- 2 The Gut-Liver Axis in Pediatric Liver Health and Disease. **2023**, 11, 597 ○
- 1 Children with Chronic Liver Disease. **2023**, 69-87 ○